237 related articles for article (PubMed ID: 33737107)
1. Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity.
Zhang R; Tu J; Liu S
Semin Cancer Biol; 2022 Jul; 82():11-25. PubMed ID: 33737107
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer stem cell: the roles and therapeutic implications.
Yang F; Xu J; Tang L; Guan X
Cell Mol Life Sci; 2017 Mar; 74(6):951-966. PubMed ID: 27530548
[TBL] [Abstract][Full Text] [Related]
3. Role of cancer stem cell ecosystem on breast cancer metastasis and related mouse models.
Peng X; Dong H; Zhang L; Liu S
Zool Res; 2024 May; 45(3):506-517. PubMed ID: 38682432
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer stem cells as novel biomarkers.
Ray SK; Mukherjee S
Clin Chim Acta; 2024 Apr; 557():117855. PubMed ID: 38453050
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications.
Wang L; Jin Z; Master RP; Maharjan CK; Carelock ME; Reccoppa TBA; Kim MC; Kolb R; Zhang W
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805056
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Ali K; Nabeel M; Mohsin F; Iqtedar M; Islam M; Rasool MF; Hashmi FK; Hussain SA; Saeed H
Med Oncol; 2024 Apr; 41(5):112. PubMed ID: 38592510
[TBL] [Abstract][Full Text] [Related]
7. Exploring the interplay between triple-negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies.
Zou Z; Luo T; Wang X; Wang B; Li Q
J Cell Physiol; 2024 May; ():. PubMed ID: 38807378
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond.
Zhang X; Powell K; Li L
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33327542
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell-immune cell crosstalk in breast tumor microenvironment: a determinant of therapeutic facet.
Guha A; Goswami KK; Sultana J; Ganguly N; Choudhury PR; Chakravarti M; Bhuniya A; Sarkar A; Bera S; Dhar S; Das J; Das T; Baral R; Bose A; Banerjee S
Front Immunol; 2023; 14():1245421. PubMed ID: 38090567
[TBL] [Abstract][Full Text] [Related]
10. A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth.
Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C
Front Pharmacol; 2023; 14():1150774. PubMed ID: 36909163
[TBL] [Abstract][Full Text] [Related]
11. A Novel Long Non-Coding RNA lnc030 Maintains Breast Cancer Stem Cell Stemness by Stabilizing SQLE mRNA and Increasing Cholesterol Synthesis.
Qin Y; Hou Y; Liu S; Zhu P; Wan X; Zhao M; Peng M; Zeng H; Li Q; Jin T; Cui X; Liu M
Adv Sci (Weinh); 2021 Jan; 8(2):2002232. PubMed ID: 33511005
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA-sequencing reveals distinct patterns of cell state heterogeneity in mouse models of breast cancer.
Yeo SK; Zhu X; Okamoto T; Hao M; Wang C; Lu P; Lu LJ; Guan JL
Elife; 2020 Aug; 9():. PubMed ID: 32840210
[TBL] [Abstract][Full Text] [Related]
13. Natural and herbal compounds targeting breast cancer, a review based on cancer stem cells.
Bozorgi A; Khazaei S; Khademi A; Khazaei M
Iran J Basic Med Sci; 2020 Aug; 23(8):970-983. PubMed ID: 32952942
[TBL] [Abstract][Full Text] [Related]
14. A developmental constraint model of cancer cell states and tumor heterogeneity.
Patel AS; Yanai I
Cell; 2024 Jun; 187(12):2907-2918. PubMed ID: 38848676
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Heterogeneity in breast cancer: clinical and therapeutic implications.
Carlino F; Solinas C; Orditura M; Bisceglia MD; Pellegrino B; Diana A
Front Oncol; 2024; 14():1321654. PubMed ID: 38469228
[No Abstract] [Full Text] [Related]
16. Breast tumours maintain a reservoir of subclonal diversity during expansion.
Minussi DC; Nicholson MD; Ye H; Davis A; Wang K; Baker T; Tarabichi M; Sei E; Du H; Rabbani M; Peng C; Hu M; Bai S; Lin YW; Schalck A; Multani A; Ma J; McDonald TO; Casasent A; Barrera A; Chen H; Lim B; Arun B; Meric-Bernstam F; Van Loo P; Michor F; Navin NE
Nature; 2021 Apr; 592(7853):302-308. PubMed ID: 33762732
[TBL] [Abstract][Full Text] [Related]
17. Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation.
Wang YH; Chan YT; Hung TH; Hung JT; Kuo MW; Wang SH; Huang Y; Lin YJ; Chen SC; Yu JC; Wu JC; Yu J; Yu AL
Oncogene; 2021 Apr; 40(16):2858-2871. PubMed ID: 33742122
[TBL] [Abstract][Full Text] [Related]
18. Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability.
Li K; Zhang TT; Zhao CX; Wang F; Cui B; Yang ZN; Lv XX; Yeerjiang Z; Yuan YF; Yu JM; Wang ZH; Zhang XW; Yu JJ; Liu SS; Shang S; Huang B; Hua F; Hu ZW
Sci Transl Med; 2021 Mar; 13(586):. PubMed ID: 33762435
[TBL] [Abstract][Full Text] [Related]
19. The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance.
Motohara T; Yoshida GJ; Katabuchi H
Semin Cancer Biol; 2021 Dec; 77():182-193. PubMed ID: 33812986
[TBL] [Abstract][Full Text] [Related]
20. Immune evasion by cancer stem cells.
Tsuchiya H; Shiota G
Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
